2010 was a tough year for medical device stocks. Investors faced up to the reality that a popular myth - that people do not meaningfully change their health care consumption because of the economy - is just not true. Investors also had to digest the impact of a suddenly much more industry-unfriendly FDA, which is imposing new (and in many cases unspecified) standards regarding safety and the trade-off with efficacy.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

All in all, the medical device industry lost about 5% in 2010, just barely missing the bottom 10 list of underperformers. In fact, in broad terms, banks (which includes many subcategories), biotechnology, solar and for-profit education were the only ones separating medical devices from the bottom.

That said, it was not all doom and gloom in the sector. In fact, many medical device companies not only outperformed the industry but did quite well in absolute terms. Here are some of the notable performers of the year. (For a quick refresher, check out A Checklist Of Successful Medical Technology Investment.)

Growth Is Growth

NxStage Medical (Nasdaq:NXTM) does not get all that much attention, but this company has brought to reality what many companies have tried (and failed) to develop for at least two decades - an at-home hemodialysis system that actually works in both a technical and practical sense. NxStage is not profitable yet, but the company is posting double-digit growth (annualizing over $100 million). On top of that, sell-side analyst interest is picking up, and institutional investors are becoming a bigger player in the stock. All of that has fueled a better than 200% jump in the stock over the last year.

DexCom (Nasdaq:DXCM)
Sometimes a better mousetrap is enough to outweigh a bad overall operating environment. DexCom has continued to see good growth and patient acceptance of its continuous glucose monitoring devices. That has meant roughly 60% revenue growth over the past 12 months, and analysts are currently still expecting at least two more years of 50%-plus top-line expansion. With diabetes still regarded as a growth market and widespread expectation of greater M&A activity, investors have seen these shares jump more than 60% in the past year. (For more, see 7 Hot Medical Device Ideas.)

Edwards Lifesciences (NYSE:EW) has likewise seen the benefits of introducing a hot new product. The Sapien transcatheter heart valve has captured hearts and minds, leading analysts to expect double-digit revenue growth, and fueling a 66% improvement in the stock - making Edwards easily the best-performing large-cap medical device stock.

Hospital Spending Lifting Off A Bottom?

A group of medical device companies has benefited from improving conditions in the hospital equipment market. Although hospital budgets are far from normal, these companies are proving that their products are something of a priority for hospitals, and they can capture scarcer spending dollars.

Volcano (Nasdaq:VOLC), a specialist in intravascular ultrasound (IVUS) imaging, has seen the stock jump nearly 70% as the company not only separates itself from Boston Scientific (NYSE:BSX), but more and more clinicians accept the clinical utility of the company's products in improving the quality of coronary care.

Sooner or later, hospitals have to replace things like hospital beds, and Hill-Rom (NYSE:HRC) is there. Trailing revenue growth here is not exceptional (up about 9%), but the stock has risen nearly 80% as the company has racked up several consecutive better-than-expected quarters, and analysts believe the worst is over in the hospital market. Likewise, cancer therapy device specialist Varian (NYSE:VAR) has not seen a big turnaround in performance yet, but analysts largely believe the worst is over and orders will pick up from here.

Other Winners

Other notable outperformers in the medical device space (with market capitalizations of $100 million or more) this year include: BSD Medical (Nasdaq:BSDM), Cooper Companies (NYSE:COO), Cyberonics (Nasdaq:CYBX), Heartware International (Nasdaq:HTWR), ZOLL Medical (Nadsaq:ZOLL) and SonoSite (Nadsaq:SONO). (For more, see There's Money To Be Made In Medical Devices.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Microsoft's Return on Equity (ROE) (MSFT)

    Discover a detailed analysis of Microsoft's historical return on equity, and learn how its ROE stacks up to its competitors in the tech industry.
  2. Stock Analysis

    Starbucks: Profiting One Cup at a Time (SBUX)

    Starbucks is everywhere. But is it a worthwhile business? Ask the shareholders who've made it one of the world's most successful companies.
  3. Stock Analysis

    How Medtronic Makes Money (MDT)

    Here's the story of an American medical device firm that covers almost every segment in medicine and recently moved to Ireland to pay less in taxes.
  4. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  5. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  6. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  7. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  8. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  9. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  10. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center